Last update :
19/11/2024
Anticancer drug   Fludarabine phosphate  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acetaflur Mexico
Asoleudox Mexico
Beneflur Mexico, Spain
Fludabin Peru
Fludacel India, Peru
Fludakebir Peru
Fludalym Turkey
Fludara Austria, Belgium, Chile, Colombia, Denmark, Egypt, Finland, France, Germany, Great Britain, Hungary, India, Iran, Ireland, Italy, Luxembourg, Malaysia, Netherlands, New Zealand, Poland, Portugal, Romania, Saudi Arabia, Sweden, Switzerland, United States of America, Venezuela
Fludarabin Iceland, Italy, Norway, Sweden, Switzerland
Fludarabina Argentina, Colombia, Peru, Romania, Spain
Fludarabine Belgium, Canada, Iran, New Zealand, Norway, Switzerland, United States of America
Fludarin India
Fludarosa Argentina
Forclina Peru
Ludabina Chile, Colombia
Mepredin Peru
Naprobin India
Neoflubin Iran
References   injection   References : Fludarabine phosphate  
Type Publication
3 Journal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Journal Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Journal Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Journal Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Journal Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Journal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Journal Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Journal Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
492 Journal Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Journal Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 Journal Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Journal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
2344 Manufacturer Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3306 Journal Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2.
3595 Manufacturer Aciclovir - Summary of Product Characteristics
Hospira 2009
3604 Manufacturer Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3637 Manufacturer Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3644 Manufacturer Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3670 Journal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3838 Manufacturer Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4398 Journal Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020

  Mentions Légales